Key result
A higher throughput MEA assay using human stem cell-derived cardiomyocytes in 48-well plates is described for profiling compound-induced effects on cardiomyocyte electrophysiology.
The MEA assay using human stem cell-derived cardiomyocytes offers a higher-throughput, electrophysiology-based method for preclinical cardiotoxicity screening.
May accelerate preclinical cardiotoxicity screening; leaves open clinical predictive value and regulatory adoption.
More relevant and reliable preclinical cardiotoxicity tests are required to improve drug safety and reduce the cost of drug development. Human stem cell-derived cardiomyocytes (hSC-CMs) provide a potential model for the development of superior assays for preclinical drug safety screening. One such hSC-CM assay that has shown significant potential for enabling more predictive drug cardiac risk assessment is the MEA assay. The Multi-electrode Array (MEA) assay is an electrophysiology-based technique that uses microelectrodes embedded in the culture surface of each well to measure fluctuations in extracellular field potential (FP) generated from spontaneously beating hSC-CMs. Perturbations to the recorded FP waveform can be used as an unbiased method of predicting the identity of ion channel(s) impacted on drug exposure. Here, a higher throughput MEA assay using hSC-CMs in 48-well MEA plates is described for profiling compound-induced effects on cardiomyocyte electrophysiology. Techniques for preparing hSC-CM monolayers in MEA plates and methods to contextualize MEA assay experimental results are also covered.
No takes yet. Share an insight, caveat, or question.
Mike Clements (2016) studied Preclinical cardiotoxicity. Multi-electrode Array (MEA) assay was evaluated. A higher throughput MEA assay using human stem cell-derived cardiomyocytes in 48-well plates is described for profiling compound-induced effects on cardiomyocyte electrophysiology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: